Logo image of FRX.CA

FENNEC PHARMACEUTICALS INC (FRX.CA) Stock Fundamental Analysis

TSX:FRX - Toronto Stock Exchange - CA31447P1009 - Common Stock - Currency: CAD

8.55  +0.97 (+12.8%)

Fundamental Rating

4

Overall FRX gets a fundamental rating of 4 out of 10. We evaluated FRX against 21 industry peers in the Biotechnology industry. FRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. FRX is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year FRX has reported negative net income.
In the past year FRX had a positive cash flow from operations.
In the past 5 years FRX always reported negative net income.
In the past 5 years FRX reported 4 times negative operating cash flow.
FRX.CA Yearly Net Income VS EBIT VS OCF VS FCFFRX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

1.2 Ratios

FRX has a Return On Assets of -0.97%. This is amongst the best in the industry. FRX outperforms 81.82% of its industry peers.
With an excellent Return On Invested Capital value of 4.86%, FRX belongs to the best of the industry, outperforming 86.36% of the companies in the same industry.
Industry RankSector Rank
ROA -0.97%
ROE N/A
ROIC 4.86%
ROA(3y)-49.57%
ROA(5y)-56.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FRX.CA Yearly ROA, ROE, ROICFRX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600 800

1.3 Margins

The Operating Margin of FRX (5.40%) is better than 86.36% of its industry peers.
With an excellent Gross Margin value of 93.30%, FRX belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
OM 5.4%
PM (TTM) N/A
GM 93.3%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FRX.CA Yearly Profit, Operating, Gross MarginsFRX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for FRX has been increased compared to 1 year ago.
Compared to 5 years ago, FRX has more shares outstanding
Compared to 1 year ago, FRX has an improved debt to assets ratio.
FRX.CA Yearly Shares OutstandingFRX.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
FRX.CA Yearly Total Debt VS Total AssetsFRX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

FRX has an Altman-Z score of -2.94. This is a bad value and indicates that FRX is not financially healthy and even has some risk of bankruptcy.
FRX has a better Altman-Z score (-2.94) than 68.18% of its industry peers.
FRX has a debt to FCF ratio of 0.67. This is a very positive value and a sign of high solvency as it would only need 0.67 years to pay back of all of its debts.
The Debt to FCF ratio of FRX (0.67) is better than 95.45% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 0.67
Altman-Z -2.94
ROIC/WACCN/A
WACCN/A
FRX.CA Yearly LT Debt VS Equity VS FCFFRX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

FRX has a Current Ratio of 6.38. This indicates that FRX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of FRX (6.38) is better than 81.82% of its industry peers.
FRX has a Quick Ratio of 6.22. This indicates that FRX is financially healthy and has no problem in meeting its short term obligations.
FRX has a better Quick ratio (6.22) than 90.91% of its industry peers.
Industry RankSector Rank
Current Ratio 6.38
Quick Ratio 6.22
FRX.CA Yearly Current Assets VS Current LiabilitesFRX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

5

3. Growth

3.1 Past

FRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 100.00%, which is quite impressive.
Looking at the last year, FRX shows a very strong growth in Revenue. The Revenue has grown by 123.55%.
EPS 1Y (TTM)100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
Revenue 1Y (TTM)123.55%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-18.59%

3.2 Future

FRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 229069.00% yearly.
Based on estimates for the next years, FRX will show a very strong growth in Revenue. The Revenue will grow by 24.62% on average per year.
EPS Next Y122375411954613120%
EPS Next 2Y13663338241.47%
EPS Next 3Y32079500%
EPS Next 5Y229069%
Revenue Next Year-15.06%
Revenue Next 2Y20.74%
Revenue Next 3Y24.08%
Revenue Next 5Y24.62%

3.3 Evolution

FRX.CA Yearly Revenue VS EstimatesFRX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
FRX.CA Yearly EPS VS EstimatesFRX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 2 3

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

FRX is valuated quite expensively with a Price/Forward Earnings ratio of 90.73.
86.36% of the companies in the same industry are more expensive than FRX, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of FRX to the average of the S&P500 Index (20.77), we can say FRX is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 90.73
FRX.CA Price Earnings VS Forward Price EarningsFRX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of FRX indicates a rather cheap valuation: FRX is cheaper than 100.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 6.3
EV/EBITDA N/A
FRX.CA Per share dataFRX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

FRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as FRX's earnings are expected to grow with 32079500.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13663338241.47%
EPS Next 3Y32079500%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FENNEC PHARMACEUTICALS INC

TSX:FRX (5/1/2025, 7:00:00 PM)

8.55

+0.97 (+12.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-10 2025-03-10/bmo
Earnings (Next)05-08 2025-05-08/bmo
Inst Owners58.82%
Inst Owner ChangeN/A
Ins Owners1.74%
Ins Owner ChangeN/A
Market Cap235.89M
Analysts85.45
Price Target20.04 (134.39%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-132.1%
Min EPS beat(2)-135.44%
Max EPS beat(2)-128.76%
EPS beat(4)1
Avg EPS beat(4)-181.91%
Min EPS beat(4)-539.32%
Max EPS beat(4)75.87%
EPS beat(8)2
Avg EPS beat(8)-140.51%
EPS beat(12)4
Avg EPS beat(12)-101.83%
EPS beat(16)6
Avg EPS beat(16)-84.49%
Revenue beat(2)0
Avg Revenue beat(2)-38.7%
Min Revenue beat(2)-53.52%
Max Revenue beat(2)-23.88%
Revenue beat(4)1
Avg Revenue beat(4)-20.29%
Min Revenue beat(4)-53.52%
Max Revenue beat(4)31.8%
Revenue beat(8)3
Avg Revenue beat(8)-10.15%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.96%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.86%
EPS NY rev (1m)0%
EPS NY rev (3m)-34.87%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.84%
Revenue NY rev (1m)-20.39%
Revenue NY rev (3m)-20.39%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 90.73
P/S 3.58
P/FCF 6.3
P/OCF 6.3
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)0
EYN/A
EPS(NY)0.09
Fwd EY1.1%
FCF(TTM)1.36
FCFY15.87%
OCF(TTM)1.36
OCFY15.87%
SpS2.39
BVpS-0.3
TBVpS-0.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.97%
ROE N/A
ROCE 6.75%
ROIC 4.86%
ROICexc 16.23%
ROICexgc 16.23%
OM 5.4%
PM (TTM) N/A
GM 93.3%
FCFM 56.75%
ROA(3y)-49.57%
ROA(5y)-56.75%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover1.06
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 0.67
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.38
Quick Ratio 6.22
Altman-Z -2.94
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
EPS Next Y122375411954613120%
EPS Next 2Y13663338241.47%
EPS Next 3Y32079500%
EPS Next 5Y229069%
Revenue 1Y (TTM)123.55%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-18.59%
Revenue Next Year-15.06%
Revenue Next 2Y20.74%
Revenue Next 3Y24.08%
Revenue Next 5Y24.62%
EBIT growth 1Y120.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1912.9%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y257.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y257.38%
OCF growth 3YN/A
OCF growth 5YN/A